Neos Therapeutics Culture Company

Mr. Thomas P. McDonnell, also known as Tom, has been the Chief Commercial Officer of Neos Therapeutics, Inc. since April 2015. Prior to joining Neos, Mr. McDonnell spent 10 years with Shire and served as Vice President of US Marketing in the Neuroscience Business Unit from December 2013 to March 2015. In this role, he led the US Product Strategy Team responsible for the commercialization of Vyvanse and Intuniv into the ADHD market. From August 2012 to November 2013, he served as Vice President and General Manager of Adult Psychiatry and led the product strategy team for all commercial and clinical development of Vyvanse in Major Depressive Disorder and Binge Eating Disorder. Previously, he held several commercial and marketing positions at Shire, including Senior Director, General Manager for Equasym XL, Senior Director of Marketing for Intuniv, Director of Marketing for Vyvanse and Senior Product Manager for Adderall XR. Before joining Shire, Mr. McDonnell held various sales, sales management and marketing positions at Abbott Laboratories and Knoll Pharmaceuticals from 1997 to 2005. He received his B.A. in Marketing from Muhlenberg College.

Mr. Russ McMahen serves as a Vice President of Research and Development at Neos Therapeutics, Inc. (alternate name PharmaFab, Inc) and also served as its Executive Vice President of Quality, Regulatory & Technical Affairs. Mr. McMahen has an experience in manufacturing operations, quality control and product development, and essential to starting many departments at PharmaFab, such as Quality Control, Quality Assurance, Regulatory Affairs, etc. Mr. McMahen served as a Vice President of Scientific Affairs at PharmaFab, Inc. He joined PharmaFab as a Director of Quality Control in July 1996. He oversaw the engineering staff and is responsible for equipment and process validation. He served at Zenith-Goldline in Shreveport, Louisiana, where he was responsible for manufacturing operations after several years of quality control and product development work. Mr. McMahen earned his BS in Chemical Engineering from Louisiana Tech University.

Mr. Richard I. Eisenstadt, also known as Rich, M.B.A., has been the Chief Financial Officer at Neos Therapeutics, Inc. since May 2014. Mr. Eisenstadt has over twenty-five years of finance leadership experience in the healthcare, life sciences and emerging technology industries. He served as the Chief Financial Officer of ArborGen Inc. since January 8, 2013. Mr. Eisenstadt was responsible for the ArborGen finance, treasury and investor relations functions. He served as Chief Financial Officer and Vice President of Finance at Ocera Therapeutics, Inc until January 4, 2013. He has an outstanding financial and analytical knowledge, strong leadership skills and an execution-based management style. Mr. Eisenstadt served as Vice President of Finance of Tranzyme, Inc. from June 2003 to January 4, 2013 and served as its Chief Financial Officer from December 2003 to December 4, 2012 and Principal Accounting Officer and Secretary until December 4, 2012. He served as the Chief Financial Officer and Vice President of Finance at Tranzyme Pharma, Inc. until January 4, 2013. Mr. Eisenstadt has an extensive track record of finance and business experience and a broad understanding of funding growth companies. He has over thirty years of finance leadership experience in the healthcare, life sciences and emerging technology industries. He joined Tranzyme in June 2003. He served as Senior Financial Advisor to several biotechnology companies with responsibilities including business and strategic planning, fundraising and financial reporting. He spent over two years as Director of Finance at Cogent Neuroscience where he was responsible for financial operations, including the establishment of two international joint ventures. Mr. Eisenstadt served for twelve years with Nimbus CD International, where he served as Director of Strategic Planning and Development and Treasury Manager and was involved in an IPO and responsible for strategic and financial planning and ensuring that adequate financing was in place to meet aggressive growth plans. He served at Nimbus included guiding it through an LBO. Mr. Eisenstadt has an MBA Degree from James Madison University and BA in Economics from University of North Carolina at Chapel Hill.

Bill Schwarzer serves as the Vice President of Sales of Neos Therapeutics, Inc.. Bill started at Neos Therapeutics, Inc. in April of 2018. Bill currently resides in Phoenix, Arizona Area.

Jeff Swalley serves as the VP, Market Access & Payer Marketing of Neos Therapeutics, Inc.. Jeff started at Neos Therapeutics, Inc. in August of 2015. Jeff currently resides in Greater Philadelphia Area.

Asif Mughal serves as the Vice President of Quality of Neos Therapeutics, Inc.. Asif started at Neos Therapeutics, Inc. in March of 2013. Asif currently resides in Dallas/Fort Worth Area.

Carolyn Sikes serves as the Vice President, Clinical Affairs (part-time) of Neos Therapeutics, Inc.. Carolyn started at Neos Therapeutics, Inc. in July of 2010. Carolyn currently resides in Greater New York City Area.